Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp Issues Q4 2012 Guidance; Revenue Guidance In Line With Analysts' Estimates; Lowers FY 2012 Revenue Guidance; Narrows FY 2012 EPS Guidance


Thursday, 18 Oct 2012 07:00am EDT 

Boston Scientific Corp announced that for fourth quarter of 2012, it expects sales in a range of $1.740 billion to $1.815 billion. The Company estimates earnings on a GAAP basis in a range of $0.06 to $0.09 per share. Adjusted earnings, excluding acquisition- and restructuring-related charges and amortization expense are estimated in a range of $0.15 to $0.18 per share (EPS). For fiscal 2012, it expects sales in a range of $7.168 billion to $7.243 billion. The Company estimates losses on a GAAP basis in a range of $2.89 to $2.86 per share. Adjusted earnings, excluding goodwill and other intangible asset impairment charges, acquisition- and divestiture-related net credits, restructuring- and litigation-related charges, discrete tax items, and amortization expense are estimated in a range of $0.63 to $0.66 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.79 billion for fourth quarter of 2012; revenue of $7.26 billion for fiscal 2012.